```
=> d his

     (FILE 'HOME' ENTERED AT 21:08:16 ON 04 SEP 2007)

     FILE 'REGISTRY' ENTERED AT 21:09:06 ON 04 SEP 2007
L1             STRUCTURE UPLOADED
L2           0 S L1 SSS
L3          19 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 21:09:38 ON 04 SEP 2007
L4           1 S L3

=> d bib abs

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2004:648488  CAPLUS
DN   141:173977
TI   Preparation of substituted anilide ligands for the thyroid receptor
IN   Washburn, William N.; Meng, Wei; Ryono, Denis E.; Ellsworth, Bruce A.;
     Ericsson, Thomas; Rahimi-Ghadim, Mahmoud; Garg, Neeraj; Malm, Johan
PA   Bristol-Myers Squibb Company, USA; Karo Bio AB
SO   PCT Int. Appl., 96 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   WO 2004067482        A2    20040812    WO 2004-US1985          20040123
     WO 2004067482        A3    20041021
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI
     US 2004180940        A1    20040916    US 2004-763878          20040123
     EP 1601641           A2    20051207    EP 2004-704944          20040123
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     JP 2006516623        T     20060706    JP 2006-502986          20040123
PRAI US 2003-442421P      P     20030124
     WO 2004-US1985       W     20040123
OS   MARPAT 141:173977
GI
```



I



II

AB Title compds. I [wherein X = O, Se, S, SO, SO2, CO, CH2, NH; R1 = H, halo, CF3, alkyl; R2 = halo, CF3, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, (hetero)aryl(oxy), (cyclo)alkoxy, arylalkoxy, COR14, CR14(OR10)R15, NR14COR15, CONR14R15, NR14SO2R16, SO2NR14R15, SR16, SOR16, SO2R16, CH2NR14R15; R3 = halo, alkyl; R5 = H, halo, alkyl; R6, R7 = independently H, halo, CN, (cyclo)alkyl; R8, R9 = independently H, halo, alkoxy, OH, CN, CF3, alkyl; R10 = independently H, alkyl; R11 = CO2R14; R12, R13 = independently H, halo, alkyl; R14, R15 = independently H, (cyclo)alkyl, (hetero)aryl(alkyl); R16 = independently (cyclo)alkyl, (hetero)aryl(alkyl); with provisos; and prodrugs, stereoisomers, and pharmaceutically acceptable salts thereof] were prepared as thyroid receptor ligands (no data). For example, 3-isopropyl-5-methylphenol was converted to 3-isopropyl-5-methyl-4-acetoxyphenol in a 3-step sequence. Bromination followed by iodination of 3-methyl-4-nitrophenol gave 3,5-dibromo-4-iodo-2-methylnitrobenzene, which was coupled with 3-isopropyl-5-methyl-4-acetoxyphenol to afford the di-Ph ether. Reduction of the nitro group to the amine using Fe in H2O/AcOH, followed by reductive amidation with Et malonyl chloride provided II. I or pharmaceutical compns. of I, alone or in combination with other therapeutic agents, are expected to be useful for preventing, inhibiting, or treating diseases or disorders associated with metabolic dysfunction or which are dependent upon the expression of a T3 regulated gene (no data).

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 X,Ak

G2 H,X

G3 C,O,S,N,Se

Structure attributes must be viewed using STN Express query preparation.

=>